Skip to main content
. 2014 Feb 10;32(8):783–790. doi: 10.1200/JCO.2013.49.3726

Fig 1.

Fig 1.

Kaplan-Meier estimates of overall survival (OS) by treatment (procarbazine, lomustine, and vincristine [PCV] plus radiotherapy [RT] or RT) for patients with (A) IDH-mutated and (B) nonmutated tumors. Hazard ratio (HR) ratio for OS for those with mutated tumors was 0.59 (95% CI, 0.40 to 0.86; P = .006); HR for those with nonmutated tumors was 1.14 (95% CI, 0.63 to 2.04; P = .67).